An Oxford University vaccine is at the forefront of development. Switzerland can easily gain access – but BAG has other plans.
This week, Switzerland has put itself in a good starting position when it comes to delivering a vaccine against Covid-19. On Friday, the federal government announced that it had secured 4.5 million doses of a future vaccine against the new virus. The American biotechnology company Moderna is in a phase 2 study with its new RNA-based vaccine. If the efficacy is also confirmed in the third clinical trial phase, the company plans to have large quantities of vaccines manufactured by the Swiss company Lonza – first at the American facility in Portsmouth, and from February also in Visp VS. He did not disclose how much the federal government pays for the delivery of the American vaccine manufactured in Switzerland. According to unconfirmed information, the purchase should amount to approximately 170 million francs – more than half of the vaccine budget of 300 million approved by the Federal Council.